Sermorelin Dosing for Black and African Ancestry Patients: What the Evidence Actually Shows

The State of the Evidence: Why There Is No Race-Specific Package Insert

Sermorelin acetate is a synthetic 29-amino-acid analog of endogenous growth-hormone-releasing hormone (GHRH 1-29). The FDA approved the original formulation (Geref) for growth hormone deficiency in children, with Walker et al. (Pediatrics, 1990) providing key early efficacy data in pediatric populations [1]. That trial, like virtually every subsequent sermorelin study, did not report ethnicity-stratified subgroup analyses.

Absence of evidence is not evidence of absence, but it does place the clinical burden squarely on the prescribing physician. The practical answer: start at the validated standard dose, layer in comorbidity-specific precautions that are statistically more common in Black and African ancestry patients, and titrate to biomarker targets rather than to a fixed ethnic dose table.

Why Ethnicity-Specific Data Are Sparse

Peptide secretagogues like sermorelin were studied predominantly in pediatric growth-failure cohorts and in small adult GH-deficiency trials during the 1990s and early 2000s. Those trials enrolled predominantly White European participants, mirroring the broader problem of underrepresentation in endocrine research documented in journals like JAMA and the Lancet [2].

The Endocrine Society's 2019 clinical practice guideline on adult GH deficiency does not specify dose adjustments by ancestry, which itself reflects the lack of stratified data [3].

What PharmGKB and Population Genomics Can Tell Us

PharmGKB catalogs gene-drug relationships for thousands of compounds. For sermorelin, no Tier 1 or Tier 2 pharmacogenomic annotation exists as of mid-2025, meaning no actionable gene-drug pair has been validated to the level that would change a standard starting dose [4]. Population-level variant frequencies still matter for downstream pathways.

Pharmacogenomics Relevant to Black and African Ancestry Patients

Pharmacogenomics cannot yet dictate a specific sermorelin milligram dose. What it can do is alert clinicians to variants that are more prevalent in African-ancestry genomes and that touch the pathways sermorelin activates.

The GHR Exon-3 Deletion Polymorphism

The growth hormone receptor (GHR) exon-3 deletion (d3-GHR) polymorphism affects GH sensitivity at the receptor level. Patients carrying two copies of the d3-GHR allele may show greater GH responsiveness per unit of stimulus compared with full-length GHR homozygotes. Allele frequency data from the 1000 Genomes Project show the d3-GHR deletion frequency varies across ancestral populations, with some African super-populations showing frequencies that differ from European reference populations by 5 to 15 percentage points [5].

Clinically, a patient who carries two d3-GHR alleles might reach mid-normal IGF-1 at a lower sermorelin dose. This is a "might," not a certainty, because individual variation swamps population-level allele frequency differences.

CYP450 Polymorphisms and Peptide Degradation

Sermorelin is cleaved primarily by tissue peptidases rather than by hepatic CYP enzymes, so the CYP2D6 and CYP2C19 polymorphisms that dominate pharmacogenomic discussions for small molecules are less directly relevant here. Still, secondary metabolic steps and binding-protein dynamics (GHBP) could be influenced by background genetic variation. The practical takeaway: CYP genotyping is not standard before starting sermorelin, but knowing a patient's CYP profile matters if you are co-prescribing drugs with narrow therapeutic windows that are CYP-metabolized.

G6PD Deficiency: Indirect but Clinically Real

G6PD deficiency affects an estimated 10 to 15% of African-ancestry males [6]. G6PD is not part of the sermorelin metabolic pathway, so deficiency does not alter sermorelin pharmacokinetics. The relevance is indirect: if a prescriber is bundling sermorelin with ancillary compounds (methylene blue, primaquine, or certain antioxidants sometimes used in peptide protocols), G6PD status becomes a safety screen. Screening before adding those adjuncts is advisable.

Hypertension, the Renin-Angiotensin System, and GH Axis Interactions

Black and African ancestry patients have roughly 1.5 to 2 times the age-adjusted hypertension prevalence compared with White patients in U.S. Epidemiological data from the CDC [7]. Growth hormone and IGF-1 affect sodium retention and vascular tone, making blood pressure an active monitoring variable during sermorelin therapy.

How GH Affects Blood Pressure

Supraphysiologic GH raises IGF-1, which promotes renal sodium reabsorption and mild fluid retention. Even at replacement doses, some patients experience a transient 2 to 5 mmHg rise in systolic blood pressure during the first 4 to 8 weeks. For a patient whose blood pressure is already at 138/88 mmHg, that shift matters.

ACE Inhibitors, ARBs, and Sermorelin Co-Prescription

Black and African ancestry patients with hypertension are more likely to be prescribed calcium channel blockers (e.g., amlodipine) as first-line therapy, because ACE inhibitors produce lower average blood pressure reductions in this group, a finding supported by the ALLHAT trial (N = 33,357) [8]. ACE inhibitors and ARBs do not pharmacokinetically interact with sermorelin in a documented way, but their effectiveness matters for managing any fluid-retention side effect. Confirm that antihypertensive therapy is well-controlled before starting sermorelin in any hypertensive patient, and recheck blood pressure at the 4-week mark.

CKD Risk and Dose Timing

CKD is disproportionately prevalent in Black and African ancestry patients, partly driven by higher rates of hypertension and diabetes and partly by APOL1 high-risk genotype variants (G1/G2) that are found almost exclusively in individuals of West African descent [9]. Sermorelin is cleared predominantly by renal filtration after proteolytic degradation. In patients with eGFR <30 mL/min/1.73m², peptide accumulation is theoretically possible, though no published PK study has quantified this precisely. A conservative approach: start at the lower end of the dose range (0.2 mcg/kg) and extend reassessment to 6 to 8 weeks rather than 4.

Standard Dosing Protocol and How to Individualize It

The widely used starting dose for adult sermorelin therapy is 0.2 to 0.3 mcg/kg subcutaneously administered at bedtime, timed to coincide with the endogenous nocturnal GH pulse. Some compounding pharmacy protocols use a fixed 200 to 300 mcg nightly dose for adults, which approximates weight-based dosing for most adults in the 70 to 100 kg range.

Titration Targets

IGF-1 is the primary titration biomarker. The target is the mid-normal range for the patient's age and sex, typically:

• Ages 18 to 30: 115 to 307 ng/mL (lab-specific reference ranges apply)
• Ages 31 to 50: 95 to 270 ng/mL
• Ages 51 to 70: 75 to 212 ng/mL

Check IGF-1 at 8 to 12 weeks. If IGF-1 remains below the lower quartile of the reference range and no adverse effects have emerged, increase by 0.05 mcg/kg increments. If IGF-1 exceeds the upper quartile, reduce by the same increment.

Monitoring Schedule for Patients with Relevant Comorbidities

Patients with hypertension, CKD, or known G6PD deficiency deserve a slightly modified monitoring schedule:

| Timepoint | Standard patient | High-comorbidity patient | |---|---|---| | Baseline | IGF-1, CBC, CMP, thyroid panel | Same + BP, eGFR, urine protein, G6PD screen if adjuncts planned | | 4 weeks | BP check (if hypertensive at baseline) | BP, weight, symptom review | | 8 to 12 weeks | IGF-1, CMP | IGF-1, CMP, eGFR if baseline <60 | | 6 months | IGF-1, fasting glucose, HbA1c | Same + BP, eGFR |

The Bedtime Timing Rationale

Sermorelin's 10 to 20 minute plasma half-life means it acts mainly by amplifying the spontaneous nocturnal GH surge that peaks around 90 to 120 minutes after sleep onset. The Endocrine Society notes that endogenous GHRH secretion is tightly coupled to slow-wave sleep architecture [3]. There is no evidence that this sleep-coupled mechanism differs by ancestry, but patients with sleep apnea (more prevalent in individuals with obesity, which disproportionately affects Black adults in the U.S.) may have blunted nocturnal GH pulses regardless of sermorelin dose [10]. Screening for and treating sleep apnea before or alongside sermorelin therapy can meaningfully improve treatment response.

Sickle Cell Trait, Sickle Cell Disease, and the GH Axis

Sickle cell trait affects approximately 8% of Black Americans, and sickle cell disease (HbSS) affects roughly 1 in 365 Black newborns according to CDC data [11]. Growth hormone deficiency and short stature are documented complications of sickle cell disease, with studies showing GH secretion abnormalities in pediatric SCD populations [12].

Should Sermorelin Be Used in Sickle Cell Disease?

No published controlled trial has evaluated sermorelin specifically in patients with sickle cell disease. GH replacement has been studied in small cohorts of SCD patients with GH deficiency, with generally favorable effects on linear growth, but the evidence base is thin. For patients with sickle cell trait (HbAS), there is no specific contraindication to sermorelin.

For patients with HbSS or HbSC disease, consult with hematology before initiating sermorelin, and avoid doses that push IGF-1 above the age-matched upper normal range, since supraphysiologic IGF-1 has been associated with procoagulant effects in some contexts.

Body Composition Differences and Their Dosing Implications

Lean body mass, fat mass distribution, and bone density differ across ancestral populations in ways that affect GH axis physiology. Black individuals on average have higher bone mineral density and greater lean mass percentage compared with White individuals at matched BMI, a finding replicated in NHANES data [13]. Because GH and IGF-1 are primary regulators of lean mass and bone turnover, a patient starting with higher baseline lean mass may respond differently to the same absolute IGF-1 increment.

This does not mandate a different starting dose. What it does mean is that body composition assessment (DEXA or bioelectrical impedance) at baseline gives the prescriber a more accurate picture of treatment response at follow-up than body weight alone.

Practical Prescribing Checklist for Black and African Ancestry Patients

Before writing the first sermorelin prescription for any patient, and especially for those with the comorbidity profile more prevalent in Black and African ancestry populations, run through these steps:

1. Measure baseline IGF-1, fasting glucose, HbA1c, CMP (including creatinine and eGFR), CBC, and thyroid panel (TSH, free T4).
2. Record seated blood pressure twice on two separate occasions. If systolic is consistently above 140 mmHg, optimize antihypertensive therapy before starting sermorelin.
3. Calculate eGFR. For eGFR <30, start at 0.2 mcg/kg and plan a 6-week first follow-up rather than 12 weeks.
4. Ask about current medications for G6PD-sensitive drug interactions if you plan to add adjunct compounds.
5. Screen for obstructive sleep apnea with a validated tool (STOP-BANG or Epworth). A score of 3 or higher warrants formal sleep study referral.
6. Document personal and family history of malignancy. Active or suspected neoplasm is a contraindication to all GH-stimulating therapies per the Endocrine Society guideline [3].
7. Confirm sickle cell status if clinically uncertain. Trait does not contraindicate sermorelin; disease warrants hematology co-management.
8. Set the first IGF-1 recheck at 8 weeks. Titrate by 0.05 mcg/kg increments based on result and symptom profile.

The Endocrine Society's 2019 guideline states: "GH therapy should be titrated based on clinical response and IGF-1 levels maintained within the normal age- and sex-adjusted reference range, to minimize the risks of GH excess." [3] That principle applies regardless of ancestry.

What Is Not Known and Why It Matters

Researchers have not conducted an ethnicity-stratified pharmacokinetic study of sermorelin. The pediatric trial by Walker et al. (Pediatrics, 1990) demonstrated that sermorelin produced statistically significant increases in growth velocity in GH-deficient children but did not report subgroup analyses by race or ethnicity [1]. More recent adult studies on GHRH analogs similarly lack stratified reporting.

This gap has two practical consequences. First, clinicians cannot cite a peer-reviewed dose-adjustment table specific to African ancestry. Second, patients from underrepresented groups who experience suboptimal response or unexpected side effects may not find their experience reflected in the published literature, making clinical reasoning more dependent on individual biomarker monitoring than on population-level generalizations.

The call to action for the field: future compounding pharmacy registries and telehealth outcome databases should collect self-reported ancestry data and publish stratified pharmacokinetic and efficacy analyses. Until that data exists, individualized IGF-1-guided titration is the most evidence-consistent approach available.